Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

Dow Jones05-13

1020 GMT - Roche Holding struck an upbeat tone on its outlook for the rest of the decade and beyond after recent positive results from late-stage drugs, Citi analysts say in a note. While the Swiss drugmaker didn't provide specific figures, it sounded incrementally optimistic on the group's growth beyond 2028, Citi says. Roche now expects pharma portfolio already on the market, together with drugs being reviewed by regulators such as giredestrant, fenebrutinib and Gazyva, to deliver strong growth and compensate for any hit from generic competition through 2030, having previously signaled a stable performance after 2028. For its diagnostics business, the company sees positive prospects once China headwinds pass in the next year, aided by the use of AI, a new blockbuster gene sequencer and expectations of growth in cancer monitoring, Citi says. Shares fall 0.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 13, 2026 06:20 ET (10:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635788706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635788706","market":"us","top_or_hot":-1,"title":"Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1020 GMT - Roche Holding struck an upbeat tone on its outlook for the rest of the decade and beyond after recent positive results from late-stage drugs, Citi analysts say in a note. While the Swiss drugmaker didn't provide specific figures, it sounded incrementally optimistic on the group's growth beyond 2028, Citi says. Roche now expects pharma portfolio already on the market, together with drugs being reviewed by regulators such as giredestrant, fenebrutinib and Gazyva, to deliver strong growth and compensate for any hit from generic competition through 2030, having previously signaled a stable performance after 2028. For its diagnostics business, the company sees positive prospects once China headwinds pass in the next year, aided by the use of AI, a new blockbuster gene sequencer and expectations of growth in cancer monitoring, Citi says. Shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2026 06:20 ET (10:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-13 18:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1020 GMT - Roche Holding struck an upbeat tone on its outlook for the rest of the decade and beyond after recent positive results from late-stage drugs, Citi analysts say in a note. While the Swiss drugmaker didn't provide specific figures, it sounded incrementally optimistic on the group's growth beyond 2028, Citi says. Roche now expects pharma portfolio already on the market, together with drugs being reviewed by regulators such as giredestrant, fenebrutinib and Gazyva, to deliver strong growth and compensate for any hit from generic competition through 2030, having previously signaled a stable performance after 2028. For its diagnostics business, the company sees positive prospects once China headwinds pass in the next year, aided by the use of AI, a new blockbuster gene sequencer and expectations of growth in cancer monitoring, Citi says. Shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2026 06:20 ET (10:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635788706","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635788706","pubTimestamp":1778667600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1020 GMT - Roche Holding struck an upbeat tone on its outlook for the rest of the decade and beyond after recent positive results from late-stage drugs, Citi analysts say in a note. While the Swiss drugmaker didn't provide specific figures, it sounded incrementally optimistic on the group's growth beyond 2028, Citi says. Roche now expects pharma portfolio already on the market, together with drugs being reviewed by regulators such as giredestrant, fenebrutinib and Gazyva, to deliver strong growth and compensate for any hit from generic competition through 2030, having previously signaled a stable performance after 2028. For its diagnostics business, the company sees positive prospects once China headwinds pass in the next year, aided by the use of AI, a new blockbuster gene sequencer and expectations of growth in cancer monitoring, Citi says. Shares fall 0.4%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4007":"制药"},"translate_title":"罗氏对长期前景持乐观态度——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"1020 GMT - Roche Holding struck an upbeat tone on its outlook for the rest of the decade and beyond after recent positive results from late-stage drugs, Citi analysts say in a note. While the Swiss drugmaker didn't provide specific figures, it sounded incrementally optimistic on the group's growth beyond 2028, Citi says. Roche now expects pharma portfolio already on the market, together with drugs being reviewed by regulators such as giredestrant, fenebrutinib and Gazyva, to deliver strong growth and compensate for any hit from generic competition through 2030, having previously signaled a stable performance after 2028. For its diagnostics business, the company sees positive prospects once China headwinds pass in the next year, aided by the use of AI, a new blockbuster gene sequencer and expectations of growth in cancer monitoring, Citi says. Shares fall 0.4%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 06:20 ET (10:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635788706","isCrawlerRequest":true}